A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

Apotex Inc., Canada’s largest drug maker, has won Health Canada approval to sell a generic form of the blockbuster Ozempic. The Toronto-based company is the second manufacturer to get an approval, ...

Java is an object-oriented programming language. To create objects and meaningfully initialize them, a developer must use a Java constructor. Constructors are a critical part of software development ...

Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up ...

April 28 (Reuters) - Health Canada has approved the first generic version of Danish drugmaker Novo Nordisk's (NOVOb.CO), opens new tab blockbuster diabetes drug Ozempic made by Indian drugmaker Dr ...

Health Canada has approved the first generic version of brand-name Ozempic. The department says Canada is the first G7 country to authorize generic semaglutide. The injectable medication is ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. A woman removes a ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo Nearly half of U.S. generic prescriptions originate in India, which relies on the Strait of ...

The cost of MiraLAX varies depending on the bottle size, the retailer, and whether you choose the brand-name version or a generic. Larger containers typically offer a better value per dose compared to ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Join us Jan. 14 for a virtual discussion about our Rx ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter ...